Libo Pharma was founded in January 2017 with a mission to develop novel drugs that address unmet needs in the clinical market. The company operates through a collaborative, modular co-development model, positioning itself as a management and core-competency hub that coordinates with external partners to drive rapid innovation. Depending on the stage of operation, Libo Pharma adopts an “outsourcing/collaborative execution model,” a “licensing model,” and a “strategic alliance model.” This highly interconnected approach helps diversify risk, improve capital efficiency, and reduce development barriers.